Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne
Launched by GALDERMA LABORATORIUM GMBH · Jan 12, 2015
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
The objective of this observational trial is to assess application and convenience of Epiduo® PUMP under daily clinical practice conditions in patients with moderate to severe inflammatory acne using this drug in topical monotherapy or in combination with other drugs. In addition, efficacy of Epiduo® and incidence of adverse events will be assessed under marketed conditions. Also, patients' body beliefs will be recorded using the dysmorphic concern questionnaire.
The observational study is designed as a multicentre study, covering all parts of Germany. Participating investigators are derma...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥9 years
- • The patient has been diagnosed with moderate to severe inflammatory acne (Leeds Grade 4-12)
- • Chest/back affected allowed, but not required
- • Topical therapy of acne with Epiduo® is indicated, the decision about treating the patient with Epiduo® has been made independently from this study
- Exclusion Criteria:
- • Pregnancy or breastfeeding
- • Acne inversa
- • Acne with preferential manisfestation of microcysts, macrocysts and macrocomedones
- • Hypersensitivity to the medication or any of the ingredients
- • Other contraindications mentioned in the Epiduo® SPC
About Galderma Laboratorium Gmbh
Galderma Laboratorium GmbH is a leading global pharmaceutical company dedicated to advancing dermatological science and improving patient outcomes through innovative research and development. With a strong focus on medical and aesthetic dermatology, Galderma specializes in delivering high-quality products and solutions that address a wide range of skin conditions. Committed to scientific excellence and patient safety, the company collaborates with healthcare professionals and researchers worldwide to conduct clinical trials that underpin its robust portfolio of prescription and over-the-counter offerings. Galderma's mission is to enhance the quality of life for patients by providing effective and accessible dermatological therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Uwe Gieler, Prof. M.D.
Principal Investigator
Universitätsklinikum Gießen und Marburg GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials